Anti-tumour response to modified self-epitopes
AssigneeScancell Limited
InventorsLinda Gillian Durrant, Victoria Anne Brentville, Rachael Louise Metheringham
Life of this patent
Estimating the term…
Abstract
Anti-tumour immune responses to modified self-epitopes. The present invention relates to the use of tumour-associated epitopes in medicine and in particular in the treatment of cancer. The epitopes stimulate an immune reaction against the tumour and have a modification selected from deimination of arginine to citrulline, nitration of tyrosine, oxidation of tryptophan and deamination of glutamine or asparagine. The invention also relates to nucleic acids comprising sequences that encode such epitopes for use in the treatment of cancer.
Claims12
A method of treating cancer in a subject identified as having MHC class II expressing tumor cells undergoing autophagy, wherein the autophagy comprises peptidylarginine deiminase 2 (PAD2) or peptidylarginine deiminase 4 (PAD4) enzyme-mediated production of self-epitopes having a modification of deimination of arginine to citrulline, wherein the resulting self-epitopes are presented on the surface of the tumor cells via MHC class II complexes, the method comprising administering to the subject a composition that comprises a Th1 adjuvant and peptides comprising at least one of the self-epitopes in an amount effective to induce IFN-γ and granzyme B-secreting CD4 T-cells that bind the MHC class II complexes presented on the surface of the tumor cells.
A method of treating cancer in a subject identified as having tumor cells undergoing autophagy, wherein the autophagy comprises peptidylarginine deiminase 2 (PAD2) or peptidylarginine deiminase 4 (PAD4) enzyme-mediated production of self-epitopes having a modification of deimination of arginine to citrulline, wherein the resulting self-epitopes are presented on the surface of the tumor cells via MHC class II complexes, the method comprising administering to the subject a composition that comprises a Th1 adjuvant and peptides comprising at least one of the self-epitopes in an amount effective to induce IFN-γ and granzyme B-secreting CD4 T-cells that bind the MHC class II complexes presented on the surface of the tumor cells, wherein the tumor cells express detectable RAET1E and/or ULBP1 proteins.
Dependencies are inferred from the claim text.